Search

Harnessing new developments in genomics to improve outcome for children with poor prognosis leukemia

At the 19th Congress of the European Hematology Association (EHA), we will learn about the state-of-the-art in management of childhood AML.

Read more

Advances from genome sequencing are paving the way to personalized treatment for leukemia and pre-leukemia

In acute myeloid leukemia (AML) our understanding of how modifications to DNA molecules that do not result in sequence change (i. e.

Read more

Treatment, medicine and hematology research: What patients want and doctors need (to know)

Jan Geissler, a Patient Advocate remarked about the Congress: “Over and above scientific updates, much can be achieved in partnership between hematologists and patients.

Read more

European Hematologists will discuss breakthroughs in blood disorders in Milan, Italy - June 12-15, 2014

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.

Read more

EHA - Access to Medicine

By reporting the unavailability of hematology medicine you are strengthening our efforts to improve patients' access to medicine across Europe. REPORT NOW

Read more

Major research funding calls are out now

First, the Innovative Medicines Initiative published its final call under the EU Seventh Framework Programme. Interestingly for hematologists, the call includes a project called ‘Blood-based biomarker assays for personalized tumour therapy: value of circulating biomarkers’.

Read more

Research must provide ‘more good news on outcomes’ while patients need simple and effective information

On behalf of EHA, professor Giovanni Martinelli and professor Theo de Witte spoke of their cutting edge research and the next steps in personalized medicine research in hematology.

Read more

Sanquin Blood Supply will culture erythrocytes for transfusion purposes

ABO-Rh-D matched transfusions result in alloimmunisation in 3-5% of recipients. Once allo-immunized, it may become very difficult to find appropriate donor erythrocytes, especially when multiple antibodies or rare combinations of antibodies are present.

Read more

Position of EHA on Research Funding

 

The challenge
The cost of biomedical research is great, but the cost of disease is immense. An ageing population and expensive innovations in medicine put an increasing burden on already stressed healthcare budgets.

Read more